

SmartPA Criteria Proposal

Drug/Drug Class:	Homozygous Familial Hypercholesterolemia (HoFH) Agents PDL Edit
First Implementation Date:	January 29, 2014
Proposed Date:	October 17, 2023
Prepared For:	MO HealthNet
Prepared By:	MO HealthNet/Conduent
Criteria Status:	<input type="checkbox"/> Existing Criteria <input checked="" type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

Executive Summary

Purpose: The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

Why Issue Selected: Familial Hypercholesterolemia (FH) is a genetic disorder characterized by high cholesterol levels, specifically high levels of low-density lipoprotein-cholesterol (LDL-C) in the blood. Patients who have one abnormal copy of the low-density lipoprotein receptor (LDLR) gene have the heterozygous form while those patients who have two abnormal copies of the LDLR gene have the homozygous form. Heterozygous FH is a common genetic disorder occurring in 1:500 people while Homozygous FH (HoFH) is much rarer, occurring in 1 in a million births. Patients with HoFH have severely elevated levels of LDL-C. Physical findings of HoFH may include premature coronary artery disease (CAD) and tendon and skin xanthomas. Treatment involves early and aggressive lipid-lowering therapies and lipoprotein apheresis. Patients with HoFH are typically less responsive to standard lipid-lowering therapies including high-intensity statins and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. Some patients with HoFH are non-responders to standard therapy.

Evkeevea[®] is an angiopoietin-like 3 (ANGPTL3) inhibitor indicated as adjunct to other LDL-C lowering therapies for the treatment of adult and pediatric patients aged 5 years and older with HoFH. Juxtapid[®] is a branded drug product indicated as an adjunct to lipid-lowering medications, treatments, and diet to reduce LDL-C, apolipoprotein B, total cholesterol (TC) and non-high density lipoprotein-cholesterol (non HDL-C) in patients with HoFH.

Total program savings for the PDL classes will be regularly reviewed.

Program-Specific Information:	Preferred Agents	Non-Preferred Agents
	<ul style="list-style-type: none"> N/A 	<ul style="list-style-type: none"> Evkeeza[®] Juxtapid[®]

Type of Criteria: Increased risk of ADE Preferred Drug List
 Appropriate Indications Clinical Edit

Data Sources: Only Administrative Databases Databases + Prescriber-Supplied

Setting & Population

- Drug class for review: Homozygous Familial Hypercholesterolemia (HoFH) Agents
- Age range: All appropriate MO HealthNet participants

Approval Criteria

- Documented diagnosis of homozygous familial hypercholesterolemia confirmed by:
 - Genetic testing **OR**
 - American Heart Association clinical criteria **AND**
- Documented compliance to the following therapies:
 - PCSK9 inhibitor therapy (defined as 90/120 days) **AND**
 - High intensity statin therapy (defined as 90/120 day) **OR**
 - Documented ADE/ADR to high intensity statin therapy **AND**
- Documentation of LDL-C lab result not meeting goal while on therapy with high-intensity statin and PCSK9 inhibitor
- For Evkeeza: Participant aged **5 years** or older
- For Juxtapid: Participant aged 18 years or older

Denial Criteria

- Participant is currently pregnant
- For Juxtapid:
 - Documented diagnosis of moderate or severe hepatic impairment
 - Dose on claim exceeds 60 mg per day
- Therapy will be denied if all approval criteria are not met

Required Documentation

Laboratory Results:
MedWatch Form:

Progress Notes:
Other:

Disposition of Edit

Denial: Exception Code "0160" (Preferred Drug List)
Rule Type: PDL

Default Approval Period

1 year

References

- Evidence-Based Medicine Analysis: "Homozygous Familial Hypercholesterolemia Products", UMKC-DIC; April 2023.
- Evidence-Based Medicine and Fiscal Analysis: "Cardiovascular: Lipotropics, Homozygous Familial Hypercholesterolemia (HoFH) Agents," Gainwell Technologies; Last updated July 21, 2023.
- Evkeeza (evinacumab-dgnb) [package insert]. Tarrytown, NY: Regeneron Pharmaceuticals; March 2023.

SmartPA PDL Proposal Form

© 2023 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.
Other company trademarks are also acknowledged.

- Juxtapid (Iomitapide) [package insert]. Dublin, Ireland: Amryt Pharmaceuticals DAC; September 2020.
- Gidding S, Champagne MA, Ferranti S, et al. The Agenda for Familial Hypercholesterolemia. *Circulation*. 2015;132(22):2167-2192. <https://doi.org/10.1161/CIR.000000000000297>.
- Facts and Comparisons eAnswers (online); 2023 Clinical Drug Information, LLC.

DRAFT